109 results
8-K
EX-99.1
FGEN
FibroGen Inc
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
and diluted share one year ago.
Research and development expenses for the second quarter of 2023 included a one-time, non-cash charge of acquired … in-process research and development expenses of $24.6 million, or $0.25 impact to net loss per basic and diluted share, resulting from the recent exclusive
10-Q
z72rjn iiik
12 May 15
Quarterly report
12:00am